Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 26 November 2013 | By Alexander Gaffney, RAC,
EU pharmacovigilance is expanding in a big way for vaccine products, the European Medicines Agency (EMA) has announced.
Under a new plan unveiled on 26 November 2013, EMA will be working with other regulatory bodies on a new five-year project known as the Accelerated Development of Vaccine Benefit-Risk Collaboration in Europe (ADVANCE), the intent of which is to better assess the risks and benefits of a vaccine throughout its lifecycle.
Unlike many drugs, vaccines are generally intended to be used in a large segment of the population. Due to limitations on trial sizes in premarket settings, the amount regulators know about the potential risks of a drug are limited as well. If, for example, the risk of an adverse event is just 1/20,000, even a 10,000-person clinical trial might not discover the risk before the vaccine is made available to consumers.
While manufacturers are already required to submit reports of adverse events, it can be difficult for fragmented regulators and other health authorities to piece together disparate signals to determine if a trend is in fact present.
That's where the ADVANCE project is set to come into play, EMA said. The project will involve EMA, the European Centre for Disease Prevention and Control, vaccine manufacturers, national public health and regulatory bodies and other outside experts.
"The goal of ADVANCE is to review, develop and test methods, data sources and procedures, which will guide the development of a European framework that can ultimately deliver data for the assessment of the benefits and risks of vaccines," EMA explained in a press statement.
"The role of the EMA in ADVANCE will be to develop and test guidance for the conduct and reporting of studies in this area," regulators added. "This best-practice guidance will include methodological standards, governance rules, a code of conduct and a communication strategy."
Participating vaccine manufacturers already include Pfizer, GlaxoSmithKline, Sanofi Pasteur, Takeda and Crucell Holland. Health authorities from Switzerland, Spain, France, Greece, Finland, Italy and the UK have signed on as well.
The project is expected to cost €10.7 million over five years, of which €5 million was contributed by the EU pharmaceutical trade group EFPIA.
EMA Press Statement
Tags: Vaccine, Adverse Events, EU, pharmacovigilance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.